Involvement of orphan esterases in side effects of drugs: acebutolol and ketoconazole
| Project/Area Number |
26860098
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 薬物代謝 / 加水分解酵素 / 薬物毒性 / アセブトロール / シトクロムP450 / 紅斑性狼瘡 |
|---|
| Outline of Final Research Achievements |
In this study, we tried to clarify the identification of esterases responsible for toxicities of two clinical drugs, acebutolol and ketoconazole. Lupus erythematosus and hepatotoxicity are known as side effects of acebutolol and ketoconazole, respectively. We found that acebutolol is hydrolyzed to acetolol by carboxyl esterase (CES) 2, followed by N-hydroxylation of acetolol by Cytochrome P450 (CYP) 2C19. Involvement of this metabolic pathway in acebutolol-induced toxicity was clarified using mice co-administered with CES and P450 inhibitors or inducers by evaluation of anti-nuclear antibody in plasma. Ketoconazole was specifically hydrolyzed to N-deacetylketoconazole by arylacetamide deacetylase (AADAC) in human liver. The involvement of AADAC in ketoconazole-induced toxicity was clarified using human hepatoma HepaRG cells with overexpression of human AADAC. These results would provide useful information for clinical and drug development.
|
Report
(3 results)
Research Products
(6 results)
